Zenas BioPharma

Contributing Author

Recent Articles by Zenas BioPharma

Dec-19	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Dec-15	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus ZBIO GlobeNewswire
Nov-12	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Nov-11	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO GlobeNewswire
Oct-27	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis ZBIO GlobeNewswire
Oct-08	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis ZBIO GlobeNewswire
Sep-02	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million ZBIO GlobeNewswire
Aug-26	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO GlobeNewswire
Aug-12	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates ZBIO GlobeNewswire
Jun-20	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
May-29	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference ZBIO GlobeNewswire
May-15	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates ZBIO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.